To the Editor:

We read with great interest the article "Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan" by Li et al,[@bib1] one of the most detailed studies in terms of patients' clinical characterization.

Interestingly, the reported asthma prevalence among patients with coronavirus disease 2019 (COVID-19) admitted to hospital was 0.9%, extremely lower than in the general population (6.4%): this is clearly unexpected because bronchial inflammation is associated with an increased susceptibility to viral infections.[@bib2] It has been hypothesized that in the case of COVID-19, inhaled corticosteroid treatment could modulate that susceptibility,[@bib3] although at the moment the relationship between COVID-19 and asthma remains unclear.[@bib4] In this context, asthma prevalence in the general population and the impact of COVID-19 outbreak in a specific area may condition the proportion of affected patients with asthma.[@bib5] Furthermore, asthma has been not specifically reported or investigated as a risk factor.[@bib5]

We revised the COVID-19 cases ([Table I](#tbl1){ref-type="table"} ) admitted in the period between March 1 and April 30, 2020, to 2 major hospitals placed in Verona (Veneto region) and Brescia (Lombardia region), in the North-east of Italy, one of the most affected areas in Europe.[@bib6] Verona and Brescia are neighboring cities, and Brescia has a greater population density. This last aspect may have conditioned the deeply different impact of COVID-19 infection in the 2 cities in terms of total amount of infected subjects and patients needing hospitalization.[@bib7] Surprisingly, we observed that the *weight* of hospital admission due to COVID-19 in patients with asthma (confirmed diagnosis by National Health System exemption code) is very similar in Verona and Brescia (1.96% and 1.92%, respectively), as well as the prevalence in the general population in the 2 areas (6%). According to the prescribed inhaled treatment, 5 of 6 patients with asthma from Verona suffered from moderate asthma; the other one, together with 15 of 20 from Brescia, was affected by mild asthma and all reported an optimal adherence rate. The other 5 cases in Brescia were affected by mild-intermittent asthma. None of the subjects reported asthma exacerbation before the admission to hospital. Mild obesity, presence of nonsevere cardiovascular diseases, and active smoking habit characterized 14 (70%) of 20 patients with asthma in Brescia Hospital, whereas in Verona 3 (50%) of 6 patients were affected by hypertension and another one by obesity and diabetes. In Verona, no one was a current smoker.Table IData related to the COVID-19 outbreak in Verona and Brescia, up to April 30, 2020Epidemiological and COVID-19 related features of the study populationBresciaVeronaPopulation198,536257,993Population density (people per km^2^)2,197.771,296.99People tested by swabs216,526 (Lombardia region)196,864 (Veneto region)People positive to SARS-CoV-212,8614,679Patients admitted because of COVID-19, n (%)1,043 (8.1% of positive cases)305 (6.5% of positive cases)Patients with asthma among patients admitted because of COVID-19, n (%)20 (1.92%)\
12 F, 8 M\
Age range: 41-77 y (mean, 61.5 y)6 (1.96%)\
3 F, 3 M\
Age range: 55-79 y (mean, 69.3 y)Prevalence of asthma in the general population6.1%6.0%[^1]

Similarly to the Wuhan report,[@bib1] our observation, the first in the Italian population, highlights that the hospitalization rate due to COVID-19 in patients with asthma is extremely low, and consistent with the asthma prevalence in the general population, more than with the *size* of the viral outbreak. This finding supports the unexpected hypothesis that asthma itself cannot be considered a risk factor for susceptibility to COVID-19. Which is the missing link?
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[^1]: *F*, Female; *M*, male; *SARS-CoV-2*, severe acute respiratory syndrome coronavirus 2.
